A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer
- 541 Downloads
The semantics of defining cancer cachexia over the last decade has resulted in uncertainty as to the prevalence. This has further hindered the recognition and subsequent treatment of this condition. Following the consensus definition for cancer cachexia in 2011, there is now a need to establish estimates of prevalence. Therefore, the primary aim of the present study was to assess the prevalence of cachexia in an unselected cancer population. A secondary aim was to assess patient-perceived need of attention to cachexia.
A cross-sectional study in hospital patients was undertaken. Key inclusion criteria were the following: age > 18 years, cancer diagnosis, and no surgery the preceding 24 h. Data on demographics, disease, performance status, symptoms, cachexia, and patients’ perceived need of attention to weight loss and nutrition were registered.
Data were available on 386 of 426 eligible patients. Median age (IQR) was 65 years (56–72), 214 (55%) were male and 302 (78%) had a performance status of 0–1 (Eastern Cooperative Oncology Group). Prevalence of cachexia (inpatients/outpatients) was 51/22%. Prevalence was highest in patients with gastrointestinal cancer (62/42%) and lung cancer (83/36%). There was no major difference in prevalence between patients with metastatic (55/24%) and localized disease (47/19%). Twenty percent of inpatients and 15% of outpatients wanted more attention to weight loss and nutrition. Cachexia (p < 0.001), symptoms of mood disorder (p < 0.001), and male gender (p < 0.01) were independently associated with increased need of attention.
Cachexia is a prevalent condition, affecting both patients with localized and metastatic cancer. Clinical attention to the condition is a sizeable unmet need.
KeywordsCachexia Weight loss Prevalence Nutrition Cancer
This study has received funding from the Cancer Fund at St. Olav’s Hospital—Trondheim University Hospital and The Liaison Committee for education, research, and innovation in Central Norway. Additionally, the European Palliative Care Research Centre has received unrestricted grants from The Norwegian Cancer Society.
Compliance with ethical standards
All procedures performed in this study were in accordance with the ethical standards of the regional ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
Stein Kaasa reports stock ownership in Eir Soloutions AS. Barry Laird reports personal fees from Chugai, outside the submitted work. Ola Magne Vagnildhaug, Trude Rakel Balstad, Sigrun Saur Almberg, Cinzia Brunelli, Anne Kari Knudsen, Morten Thronæs, and Tora Skeidsvoll Solheim have nothing to disclose.
- 1.Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology 12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7 CrossRefPubMedGoogle Scholar
- 9.Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH, Stone P, Kaasa S, Fearon K, Strasser F, European Palliative Care Research C (2011) Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 80(1):114–144. https://doi.org/10.1016/j.critrevonc.2010.10.004 CrossRefPubMedGoogle Scholar
- 10.Wallengren O, Lundholm K, Bosaeus I (2013)) Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Supportive Care Cancer : Off J Multinatl Assoc Support Care Cancer 21(6):1569–1577. https://doi.org/10.1007/s00520-012-1697-z CrossRefGoogle Scholar
- 12.Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr., Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69 (4):491–497, DOI: https://doi.org/10.1016/S0149-2918(05)80001-3 CrossRefGoogle Scholar
- 13.Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. The Lancet Oncology 17(4):519–531. https://doi.org/10.1016/S1470-2045(15)00558-6 CrossRefPubMedGoogle Scholar
- 20.Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, Baracos VE, Fearon K, Strasser F, Kaasa S, on behalf of E-I (2014) Validation of the consensus-definition for cancer cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol: Off J Eur Soc Med Oncol/ ESMO 25(8):1635–1642. https://doi.org/10.1093/annonc/mdu086 CrossRefGoogle Scholar
- 25.Thronaes M, Raj SX, Brunelli C, Almberg SS, Vagnildhaug OM, Bruheim S, Helgheim B, Kaasa S, Knudsen AK (2016) Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5 years apart. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 24(6):2565–2574. https://doi.org/10.1007/s00520-015-3064-3 CrossRefGoogle Scholar
- 32.Blauwhoff-Buskermolen S, Langius JAE, Becker A, Verheul HMW, de van der Schueren MAE (2017) The influence of different muscle mass measurements on the diagnosis of cancer cachexia. J Cachexia Sarcopenia Muscle 8(4):615–622. https://doi.org/10.1002/jcsm.12200 CrossRefPubMedPubMedCentralGoogle Scholar